Regeneron Quarterly Revenue Climbs 36% to $5.1 Billion as Sanofi Partnership Expands

Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.116 billion on Friday, October 30, a 36% increase from $3.754 billion a year earlier, supported by stronger medicine sales and income from its pharmaceutical collaborations.

The New York-based biotechnology company reported net income under generally accepted accounting principles of $1.949 billion, compared with $1.460 billion in the same quarter last year. Diluted earnings per share rose 35% to $18.45. On the company's adjusted, non-GAAP measure, diluted earnings per share increased 70% to $20.07. The adjusted figure excludes specified accounting items and should not be confused with statutory profit.

The company highlighted growth across several medicines. US sales of its higher-dose eye treatment EYLEA HD increased 62% to $699 million, while worldwide sales of cancer medicine Libtayo rose 51% to $550 million. Global sales of Dupixent, which are recorded by partner Sanofi rather than booked as Regeneron product sales, rose 35% to $6.5 billion. That distinction matters when comparing individual product sales with Regeneron's own reported revenue.

Regeneron also provided more detail about an expanded collaboration with Sanofi covering next-generation, longer-acting antibodies for immune-related diseases. The agreement includes a $1 billion upfront payment, expected to be recognised as collaboration revenue in the fourth quarter, and potential future milestones of up to $7 billion. Those additional payments depend on development, regulatory and commercial outcomes; they are not guaranteed revenue.

The companies will share development and commercialisation costs for the new programmes equally, and would divide global profits equally if any of the products reach the market. The October 30 earnings report describes both completed financial performance and prospective research programmes, whose clinical and commercial outcomes remain uncertain.